{"disease":{"id":"deaf-blind","name":"deaf blind"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05964725","title":"The Study on Effect and Neural Network Mechanism of Transcranial Direct Current Stimulation for Sudden Deafness With Tinnitus","phase":"NA","overall_status":"UNKNOWN","enrollment_count":86,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03780257","title":"Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"ProQR Therapeutics","has_results":false},{"nct_id":"NCT05158296","title":"Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05176717","title":"Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Laboratoires Thea","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}